TP53 and myelodysplastic syndrome: This is in line with previous findings about the prognostic heterogeneity of these mutations in myeloid malignancies, and particularly those affecting TP53. Bernard et al. (2020) observed that monoallelic TP53 hits did not influence prognosis in myelodysplastic syndrome patients, whereas multi-hit somatic events in TP53 were independently associated with adverse outcome (23).